Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Information provided by:
Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT01047072
First received: January 11, 2010
Last updated: October 29, 2012
Last verified: October 2012

January 11, 2010
October 29, 2012
Not Provided
September 2017   (final data collection date for primary outcome measure)
Event-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Event-free survival [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01047072 on ClinicalTrials.gov Archive Site
  • Event-free survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Time to progression [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Time to progression [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Incidence of initiation of any SSC disease-modifying therapy other than that specified in the protocol treatment arms [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Incidence of definite and probable viral, fungal, and bacterial infections [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Median time to engraftment as defined as having greater than or equal to 5% donor T cells in the peripheral blood (donor T cell chimerism) [ Time Frame: From date of transplant to time of engraftment ] [ Designated as safety issue: No ]
  • Rate of primary graft failure [ Time Frame: Day 56 ] [ Designated as safety issue: No ]
  • Rate of secondary graft failure [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Probability of acute and chronic GVHD [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
  • Treatment-related mortality [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
  • Regimen-related toxicity as assessed by CTCAE version 3.0 [ Time Frame: 2 and 5 years ] [ Designated as safety issue: Yes ]
  • Development of infectious complications [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
  • Incidence of primary and secondary graft failure (Arm I) [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
  • Incidence and severity of graft versus host disease (Arm I) [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
  • Disease activation/progression [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
  • Disease response [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
  • Dermal fibrosis and vasculopathy [ Time Frame: 2 and 5 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
Phase II Clinical Trial of Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

The purpose of the study is to see how well reduced intensity conditioning followed by a stem cell transplant from a donor (allogeneic) works in treating patients with severe systemic sclerosis. In an allogeneic stem cell transplant procedure, stem cells are taken from a healthy donor and transplanted into the patient. Stem cells can be donated by a family member or an unrelated donor who is a complete tissue type match.

PRIMARY OBJECTIVES:

I. To evaluate the overall effects of allogeneic hematopoietic cell transplantation (HCT) in systemic sclerosis (SSc).

II. To assess the potential efficacy, in terms of event-free survival (EFS) at 2 (part 1) and 5 (part 2) years, of allogeneic HCT as treatment for patients with severe SSc.

SECONDARY OBJECTIVES:

I. To evaluate the rate of complications of allogeneic HCT after nonmyeloablative conditioning including the incidence of graft rejection, regimen-related toxicities, severe acute and chronic graft-vs-host disease (GVHD), infectious complications, treatment-related mortality (TRM), and overall survival.

II. To evaluate treatment effects on disease activation/progression, as indicated by measures of cardiac, pulmonary, gastrointestinal and renal function, as well as skin thickness, overall functional assessment (SHAQ), use of concomitant disease-modifying antirheumatic drugs (DMARDs), and occurrence of myositis.

III. To evaluate disease responses after nonmyeloablative conditioning and allogeneic HCT or immunomodulatory therapy, assessing skin disease by modified Rodnan Skin Score (mRSS), pulmonary function as measured by diffusing capacity of the lung for carbon monoxide (DLCO) and forced vital capacity (FVC), Modified Scleroderma Health Assessment Questionnaire (SHAQ), and Quality of Life using Short Form 36 (SF36).

IV. To evaluate, by mechanistic studies, of the effect of allogeneic HCT on dermal fibrosis and vasculopathy.

V. To evaluate the late complications of allogeneic HCT after nonmyeloablative conditioning including the incidence and prevalence of chronic GVHD and time to discontinue immunosuppression, infectious complications, TRM and overall survival.

VI. To evaluate the treatment effects on disease activation/ progression, as indicated by measures of cardiac, pulmonary, gastrointestinal and renal function, as well as skin thickness, overall functional assessment (SHAQ), use of concomitant DMARDs, and occurrence of myositis.

VII. To evaluate disease responses after nonmyeloablative conditioning and allogeneic HCT or immunomodulatory therapy, assessing skin disease by modified Rodnan Skin Score (mRSS), pulmonary function as measured by DLCO and FVC, Modified Scleroderma Health Assessment Questionnaire (SHAQ), and Quality of Life using Short Form 36 (SF36).

OUTLINE: Patients are assigned to 1 of 2 treatment arms and receive nonmyeloablative conditioning followed by an allogeneic peripheral blood stem cell transplantation. Treatment in both arms continues in the absence of disease progression of unacceptable toxicity.

ARM I (transplant): Patients receive fludarabine intravenously (IV) on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus orally (PO) twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.

ARM II (nontransplant): Patients will receive immunosuppressive therapy based on their history. The 3 options that they may receive include 1.)mycophenolate mofetil PO twice daily for 16 months, 2.) Rituximab IV on days 1 and 15 and then repeated at 6 months, and 3.) Cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.

After completion of study treatment, patients are followed up periodically for 5 years.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Systemic Scleroderma
  • Drug: fludarabine phosphate
    Given IV
    Other Names:
    • 2-F-ara-AMP
    • Beneflur
    • Fludara
  • Radiation: total-body irradiation
    Undergo total-body irradiation
    Other Name: TBI
  • Drug: tacrolimus
    Given orally
    Other Names:
    • FK 506
    • Prograf
  • Drug: mycophenolate mofetil
    Given orally
    Other Names:
    • Cellcept
    • MMF
  • Biological: rituximab
    Given IV
    Other Names:
    • IDEC-C2B8
    • IDEC-C2B8 monoclonal antibody
    • Mabthera
    • MOAB IDEC-C2B8
    • Rituxan
  • Drug: cyclophosphamide
    Given orally
    Other Names:
    • CPM
    • CTX
    • Cytoxan
    • Endoxan
    • Endoxana
  • Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
    Undergo transplantation
  • Procedure: peripheral blood stem cell transplantation
    Undergo transplantation
    Other Names:
    • PBPC transplantation
    • PBSC transplantation
    • peripheral blood progenitor cell transplantation
    • transplantation, peripheral blood stem cell
  • Experimental: Arm I (transplant)
    Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
    Interventions:
    • Drug: fludarabine phosphate
    • Radiation: total-body irradiation
    • Drug: tacrolimus
    • Drug: mycophenolate mofetil
    • Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
    • Procedure: peripheral blood stem cell transplantation
  • Active Comparator: Arm II (nontransplant)
    Patients receive mycophenolate mofetil PO twice daily for 16 months, rituximab IV on days 1 and 15 and then repeated at 6 months, and cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.
    Interventions:
    • Drug: mycophenolate mofetil
    • Biological: rituximab
    • Drug: cyclophosphamide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
September 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with severe SSc as defined by the American College of Rheumatology and at high-risk for a fatal outcome based on the following prognostic factors from groups 1-5:

    • Group 1: Patients with 1) both a. and b. below; and 2) at least one of c., d. or e:

      • a. Diffuse cutaneous scleroderma with skin score of >= 16 (modified Rodnan skin scale)
      • b. Duration of systemic sclerosis =< 5 years from the onset of first non-Raynaud's symptom
      • c. Presence of interstitial lung disease with FVC or DLCOcorr =< 70% of predicted and evidence of alveolitis (abnormal bronchoalveolar lavage [BAL] or high resolution chest computed tomography [CT] scan)
      • d. Left heart failure with left ventricular ejection Fraction (LVEF) < 50% or pericardial effusion (mild-moderate) or 2nd or 3rd Atrial-Ventricular (AV) block; Myocardial disease not secondary to SSc must be excluded by a cardiologist
      • e. History of SSc-related renal disease that is not active at the time of screening; History of scleroderma hypertensive renal crisis is included in this criterion
    • Group 2: Patients will have progressive pulmonary disease as the primary indication for transplant as defined by a decrease in the FVC or DLCO by 15 percent or greater in the previous 12-month period. In addition, patients may have either less skin involvement than group 1 (mRSS < 16) if they have a history of diffuse cutaneous disease and the FVC or DLCOcorr is < 70% or both FVC and DLCOcorr >= 70% if they have diffuse cutaneous disease (mRSS > 16) at screening for the study; Patients must also have evidence of alveolitis as defined by abnormal chest CT or BAL
    • Group 3: Have progressive active SSc after prior autologous HCT based on the presence of progressive pulmonary disease; This will be defined by a decrease in the FVC since prior autologous transplant by 10 percent or greater, or DLCO since prior autologous transplant by 15 percent or greater in addition to evidence of alveolitis as defined by chest CT changes or BAL; If patients had prior autologous HCT on the SCOT clinical trial, they must have failed based on the defined study endpoints and be approved by the protocol principal investigator (PI)
    • Group 4: Patients who meet group 1 inclusion criteria but have FVC or DLCO < 70% plus have had an adverse event to cyclophosphamide preventing its further use (i.e., hemorrhagic cystitis, leucopenia with WBC, 2000 or ANC < 1000 or platelet count < 100,000 and other adverse events)
    • Group 5: Diffuse scleroderma with disease duration =< 2 years since development of first sign of skin thickening plus modified Rodnan skin score >= 25 plus ESR > 25 mm/1st hour and/or Hb < 11 g/dL not explained by causes other than active scleroderma.
  2. Unless patients have a DLCOcorr less than 45%, patients must have failed either oral or intravenous cyclophosphamide regimen defined as:

    • IV cyclophosphamide administration for > 6 months or a total cumulative IV dose of 6 g/m^2, or
    • oral cyclophosphamide administration for > 6 months regardless of dose, or
    • combination of oral and IV cyclophosphamide for > 6 months independent of dose
  3. Patient must have a sibling who is a) HLA-identical and b) could serve as a donor of a peripheral blood stem cell graft to be placed on the transplant arm or an unrelated donor matched at HLA-A, B, C, DRB1 and DQB1. Patients without an HLA-identical sibling or an HLA-matched unrelated donor that meet the above criteria will be placed on the non-transplant arm

DONOR:

  • The donor must be an HLA-identical sibling of the patient or an HLA-matched unrelated donor.
  • If the donor has reached the age of assent, then they must have completed the local institutional review board (IRB) assent process.
  • Donor must consent to G-CSF administration and to leukapheresis for HSC collection.
  • Donor must have adequate veins for leukapheresis or agree to placement of central venous catheter (femoral, subclavian).
  • Age 12-75 years; Pediatric donors must be > 50 kg body weight.

Exclusion Criteria:

  • Eligible for the NIH-sponsored randomized clinical trial (SCOT)
  • Fertile men or women unwilling to use contraceptive techniques during and for 12 months or until immunosuppression is discontinued following transplantation
  • Evidence of ongoing active infection
  • Pregnancy
  • Subjects with pulmonary, cardiac, hepatic, or renal impairment that would limit their ability to receive therapy and compromise their survival. This includes but is not restricted to, subjects with any of the following:

    • Severe pulmonary dysfunction defined as:

      1. A hemoglobin corrected DLCOcorr < 30% or FVC < 40% of predicted; or
      2. O2 saturation < 92% at rest without supplemental oxygen; or
      3. PO2 < 70 mmHg or pCO2 > 50 mmHg without supplemental oxygen
    • Significant uncontrolled pulmonary hypertension defined as:

      1. Pulmonary artery peak systolic pressure > 45 mmHg by echocardiogram and mean pulmonary artery pressure by right heart catheterization exceeding 32 mmHg at rest or 42 mm Hg during exercise; or
      2. New York Heart Association (NYHA)/World Health Organization (WHO) classification for pulmonary hypertension, Class III or IV
    • Cardiac: Uncontrolled clinically significant arrhythmias; clinical evidence of significant cardiac disease (NYHA Class III or IV); LVEF < 40% by echocardiogram
    • Significant renal pathology, defined as:

      1. Estimated CrCl < 60 mL/min (using Cockcroft-Gault formula based on actual body weight) or serum creatinine > 2.0 mg/dL OR
      2. Active, untreated SSc renal crisis at the time of enrollment
    • Active hepatitis or liver biopsy evidence of cirrhosis or periportal fibrosis. Total bilirubin > 2.5 x the upper limit of normal (and not related to Gilbert's syndrome) and/or Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 4 x the upper limit of normal
    • Patients with poorly controlled hypertension
    • Patients whose life expectancy is severely limited by illness other than autoimmune disease
  • DONOR:

    • Identical twin of patient
    • Female donors who are pregnant (positive B-HCG) or breastfeeding
    • Infection with human immunodeficiency virus (HIV) or active viral hepatitis (B or C)
    • Known allergy to G-CSF
    • Current serious systemic illness
    • Uncontrolled bacterial, viral or fungal infection (currently taking medication and progression of clinical symptoms)
    • Donors receiving experimental therapy or investigational agents
    • Donors with cancer other than treated basal cell or carcinoma in situ of cervix; Cancer treated with curative intent > 2 years previous will be reviewed on a case-by-case basis by a Protocol Chair or Medical Monitor
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01047072
2363.00, NCI-2012-00139
Yes
Georges, George, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
National Cancer Institute (NCI)
Principal Investigator: George Georges Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Fred Hutchinson Cancer Research Center
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP